{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:14:59Z","timestamp":1790266499593,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2242,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST103-2314-B-037-004-MY3"],"award-info":[{"award-number":["MOST103-2314-B-037-004-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Center for Environmental Medicine, Kaohsiung Medical University","award":["KMU-TP104A34"],"award-info":[{"award-number":["KMU-TP104A34"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH105-5R64"],"award-info":[{"award-number":["KMUH105-5R64"]}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s13311-017-0512-4","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T09:29:10Z","timestamp":1486978150000},"page":"784-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study"],"prefix":"10.1016","volume":"14","author":[{"given":"Shu-Yu","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-017-0512-4_bib1","unstructured":"Department of Statistics, Ministry of the Interior, Taiwan, [online]. Available at: http:\/\/www.moi.gov.tw\/stat\/. Accessed January 25, 2017."},{"key":"10.1007\/s13311-017-0512-4_bib2","unstructured":"The China Post news staff. Taiwan must address the challenges of an aging society [online]. Available at: http:\/\/www.chinapost.com.tw\/editorial\/taiwan-issues\/2013\/10\/13\/391104\/Taiwan-must.htm. Accessed October 13, 2013."},{"issue":"3","key":"10.1007\/s13311-017-0512-4_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement"},{"issue":"128","key":"10.1007\/s13311-017-0512-4_bib4","first-page":"150","article-title":"Drugs for Alzheimer's disease: best avoided. No therapeutic advantage","volume":"21","year":"2012","journal-title":"Prescrire international"},{"key":"10.1007\/s13311-017-0512-4_bib5","article-title":"Donepezil for mild cognitive impairment","volume":"3","author":"Birks","year":"2006","journal-title":"The Cochrane database of systematic reviews."},{"issue":"4","key":"10.1007\/s13311-017-0512-4_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3233\/JAD-2009-0975","article-title":"Vascular factors in diabetes and Alzheimer's disease","volume":"16","author":"Taguchi","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1007\/s13311-017-0512-4_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1007\/s13311-017-0512-4_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"The Lancet Neurology"},{"issue":"2","key":"10.1007\/s13311-017-0512-4_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/STROKEAHA.111.635417","article-title":"Cilostazol Reduces the Risk of Hemorrhagic Infarction After Administration of Tissue-Type Plasminogen Activator in a Murine Stroke Model","volume":"43","author":"Kasahara","year":"2012","journal-title":"Stroke"},{"issue":"5","key":"10.1007\/s13311-017-0512-4_bib10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/01.STR.20.5.668","article-title":"Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia","volume":"20","author":"Tanaka","year":"1989","journal-title":"Stroke"},{"issue":"4","key":"10.1007\/s13311-017-0512-4_bib11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2011.04.068","article-title":"Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation","volume":"408","author":"Park","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-017-0512-4_bib12","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations [online]. Available at: https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/. Accessed December 20, 2016."},{"issue":"4","key":"10.1007\/s13311-017-0512-4_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10654-010-9451-7","article-title":"Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies","volume":"25","author":"Stricker","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"10.1007\/s13311-017-0512-4_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/138161206775474323","article-title":"Cilostazol: therapeutic potential against focal cerebral ischemic damage","volume":"12","author":"Hong","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1007\/s13311-017-0512-4_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1440-1681.12495","article-title":"Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention","volume":"43","author":"Zheng","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"10.1007\/s13311-017-0512-4_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.01.026","article-title":"Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis","volume":"25","author":"Wang","year":"2016","journal-title":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association"},{"key":"10.1007\/s13311-017-0512-4_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ahj.2015.12.014","article-title":"Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial","volume":"173","author":"Ueda","year":"2016","journal-title":"Am Heart J."},{"issue":"1","key":"10.1007\/s13311-017-0512-4_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.brainres.2006.01.088","article-title":"Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion","volume":"1082","author":"Lee","year":"2006","journal-title":"Brain research"},{"issue":"3","key":"10.1007\/s13311-017-0512-4_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1381612820666140826114601","article-title":"Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview","volume":"21","author":"Heckman","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1007\/s13311-017-0512-4_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/JGP.0b013e31819431ea","article-title":"A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study","volume":"17","author":"Arai","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1007\/s13311-017-0512-4_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/jscd.2001.24657","article-title":"Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction","volume":"10","author":"Mochizuki","year":"2001","journal-title":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association"},{"issue":"29","key":"10.1007\/s13311-017-0512-4_bib22","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1523\/JNEUROSCI.5291-04.2005","article-title":"Amyloid-beta peptide inhibits activation of the nitric oxide\/cGMP\/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity","volume":"25","author":"Puzzo","year":"2005","journal-title":"The Journal of neuroscience : the official journal of the Society for Neuroscience"},{"issue":"6","key":"10.1007\/s13311-017-0512-4_bib23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/01.STR.0000221783.08037.a9","article-title":"Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion","volume":"37","author":"Watanabe","year":"2006","journal-title":"Stroke"},{"key":"10.1007\/s13311-017-0512-4_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2007.09.016","article-title":"Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats","volume":"1185","author":"Lee","year":"2007","journal-title":"Brain research."},{"issue":"4","key":"10.1007\/s13311-017-0512-4_bib25","first-page":"208","article-title":"Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type","volume":"18","author":"Bellew","year":"2004","journal-title":"Alzheimer disease and associated disorders"},{"issue":"3","key":"10.1007\/s13311-017-0512-4_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/psyg.12021","article-title":"Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis","volume":"13","author":"Taguchi","year":"2013","journal-title":"Psychogeriatrics"},{"key":"10.1007\/s13311-017-0512-4_bib27","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01409564 (NLM Identifier: NCT01409564). Accessed July 12, 2016."},{"issue":"2","key":"10.1007\/s13311-017-0512-4_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089516","article-title":"Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study","volume":"9","author":"Ihara","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1007\/s13311-017-0512-4_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1447-0594.2012.00866.x","article-title":"Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study","volume":"13","author":"Sakurai","year":"2013","journal-title":"Geriatr Gerontol Int"},{"issue":"6","key":"10.1007\/s13311-017-0512-4_bib30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/VHRM.S3160","article-title":"Safety and efficacy of cilostazol in the management of intermittent claudication","volume":"4","author":"Chi","year":"2008","journal-title":"Vascular Health and Risk Management"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-017-0512-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:59:49Z","timestamp":1761807589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1878747923014563"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0512-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0512-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}